Dow Jones
31.037,68 +69,86 (+0,23%) Nasdaq
11.361,85 +39,61 (+0,35%) Nikkei 225
26.435,61 +327,96 (+1,26%) EUR/USD
1,0202 +0,0018 (+0,17%) BTC-EUR
19.984,24 +116,95 (+0,59%) CMC Crypto 200
443,00 +7,48 (+1,72%)
China Resources Beer (Holdings) Company Limited (0291.HK)
- GlobeNewswire
Zealand Pharma Completes Enrollment in Phase 3 Trial of Dasiglucagon in Children with Congenital Hyperinsulinism (CHI)
Company announcement – No. 4 / 2022 Zealand Pharma Completes Enrollment in Phase 3 Trial of Dasiglucagon in Children with Congenital Hyperinsulinism (CHI) Top-line results expected in the second quarter of 2022Pending positive results, Zealand intends to file for marketing approval with the US Food and Drug Administration Copenhagen, DK and Boston, MA, U.S. February 15, 2022 – Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no. 20045078,) a biotechnology company focused on the discovery, development and
- GlobeNewswire
Zealand Pharma increases its share capital as a consequence of exercise of employee warrants
Company announcement – No. 74 / 2021 Zealand Pharma increases its share capital as a consequence of exercise of employee warrants Copenhagen, DK and Boston, MA, U.S. December 10, 2021 – Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company focused on the discovery, development and commercialization of innovative peptide-based medicines, has increased its share capital by a nominal amount of DKK 5,400 divided into 5,400 new shares with a nominal value of DKK 1 each. The in
- GlobeNewswire
Zealand Pharma major shareholder announcement: The Capital Group Companies, 2021
Company announcement – No. 73 / 2021 Zealand Pharma major shareholder announcement: The Capital Group Companies, 2021 Copenhagen, DK and Boston, MA, November 30, 2021 – Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no. 20 04 50 78), a Copenhagen-based biotechnology company focused on the discovery and development of innovative peptide-based medicines, today announces the receipt of notification pursuant to Section 38 of the Danish Capital Markets Act from the following major shareholders: T
